Biogen's strong Alzheimer's drug data may benefit Vigil Neuroscience - Jefferies

Vigil Neuroscience

28/09/2022 19:31

** Strong data from Biogen Inc  BIIB.O  and Eisai Co's
 4523.T  second Alzheimer's drug, lecanemab, will benefit Vigil
Neuroscience  VIGL.O , says Jefferies  urn:newsml:reuters.com:*:nL1N30Y2XV  urn:newsml:reuters.com:*:nL1N30Z0O8
    ** VIGL is conducting pre-clinical trial on a small molecule
drug to treat the memory-robbing disease, which is based on a
different mechanism to BIIB-Eisai's but is linked to the same
amyloid deposits that lecanemab targets - brokerage
    ** VIGL is developing the only oral drug in its category for
Alzheimer's, which may lead to minimal safety risks if at all -
Jefferies
    ** Brokerage expects VIGL's oral drug to enter early stage
studies later in 2023
    ** "We think VIGL could appeal to investors looking for
interesting stories" 
    ** VIGL shares up 1% at $8.96 in afternoon trade
    ** 5 of 6 brokerages rate the stock "buy" or higher, 1
"hold"; their median PT is $21
 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))